Advertisement

Hormones

, Volume 14, Issue 2, pp 272–279 | Cite as

Human kallikrein 10 in surgically removed human pituitary adenomas

  • Fabio Rotondo
  • Antonio Di Ieva
  • Kaiman Kovacs
  • Michael D. Cusimano
  • Luis V. Syro
  • Eleftherios P. Diamandis
  • George M. Yousef
Research paper

Abstract

OBJECTIVE

Human kallikrein-like peptidase 10 (KLK10), a serine protease, plays an important role in the regulation of cell proliferation and tumor growth. In this work, we investigated KLK10 immunoexpression in various types of surgically removed human pituitary tumors.

DESIGN

Specimens were fixed in formalin and embedded in paraffin. Immunostaining was performed by the streptavidin-biotin-peroxidase complex protocol using the LSAB+ Kit and a KLK10-specific rabbit polyclonal antibody.

RESULTS

Results showed that both treated and untreated prolactin-producing pituitary adenomas and carcinomas as well as TSH-producing pituitary adenomas and carcinomas were conclusively immunopositive for KLK10. Immunostaining was mainly localized in the cytoplasm and was clearly visible in many adenoma cells. In various other tumor types (oncocytoma, gonadotroph, somatotroph adenomas, and carcinomas), cytoplasmic immunopositivity was mild to moderate and seen only in a few unevenly distributed adenoma cells. Immunopositivity in the nuclei of various tumor types, as well as dual cytoplasmic and nuclear localization of KLK10 in some of the tumor types, was an intriguing finding. Immunoexpression in GH-producing adenomas exposed to octreotide, a long-acting somatostatin analog, was significantly increased when compared to unexposed GH-producing tumors.

CONCLUSION

More studies are needed to ascertain the role of KLK10 in pituitary tumor development, prognosis, and progression. The question of whether genetic abnormalities and the microenvironment can affect KLK10 immunoexpression should also be investigated.

Key words

Human kallikrein 10 Immunohistochemistry Pathology Pituitary adenoma Prognostic marker 

References

  1. 1.
    Yousef GM, Diamandis EP, 2001 The new human tissue kallikrein gene family: structure, function and association to diasease. Endocr Rev 22: 184–204.PubMedGoogle Scholar
  2. 2.
    Yousef GM, Chang A, Scorilas A, Diamandis EP, 2000 Genomic organization of the human kallikrein gene family of chromosome 19q13.3-13.4. Biochem Biophys Res Commun 276: 125–133.CrossRefGoogle Scholar
  3. 3.
    Diamandis EP, Yousef GM, Clements J, et al, 2000 New nomenclature for the human tissue kallikrein family. Clin Chem 46: 1855–1858.PubMedGoogle Scholar
  4. 4.
    Yousef GM, Luo LY, Diamandis EP, 1999 Identification of novel human kallikrein-like genes on chromosome 19q13.3-q13.4. Anticancer Res 19: 2843–2852.PubMedGoogle Scholar
  5. 5.
    Yousef GM, Kishi T, Diamandis EP, 2003 Role of kallikrein enzymes in the central nervous system. Clin Chim Acta 329:1–8.CrossRefGoogle Scholar
  6. 6.
    Borgoño CA, Diamandis EP, 2004 The emerging roles of human tissue kallikrein in cancer. Nat Rev Cancer 4: 876–890.CrossRefGoogle Scholar
  7. 7.
    Petraki CD, Karavana VN, Luo LY, Diamandis EP, 2002 Human kallikrein 10 expression in normal tissues by immunohistochemistry. J Histochem Cytochem 50: 1247–1261.CrossRefGoogle Scholar
  8. 8.
    Petraki CD, Gregorakis AK, Papanastasiou PA, et al, 2003 Immunohistochemical localization of human kallikreins 6, 10 and 13 in beign and malignant prostatic tissue. Prostate Cancer Prostatic Dis 6: 223–227.CrossRefGoogle Scholar
  9. 9.
    Borgono CA, Michael IP, Diamandis EP, 2004 Human tissue kallikreins: physiologic roles and applications in cancer. Mol Cancer Res 2: 257–280.PubMedGoogle Scholar
  10. 10.
    Goyal J, Smith KM, Cowan JM, Wazer DE, Lee SW, Band V, 1998 The role for NES1 serine protease as a novel tumor suppressor. Cancer Res 58: 4782–4786.PubMedGoogle Scholar
  11. 11.
    Dhar S, Bhargava R, Yunes M, et al, 2001 Analysis of normal epithelial cell specific-1 (NES1)/kallikrein 10 mRNA expression by in-situ hybridization, a novel marker for breast cancer. Clin Cancer Res 7: 3393–3398.PubMedGoogle Scholar
  12. 12.
    Luo LY, Meyts ER, Jung K, Diamandis EP, 2001 Expression of the normal epithelial cell-specific 1 (NES1, KLK10) candidate tumour suppressor gene in normal and malignant testicular tissue. Br J Cancer 85: 220–224.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Liu XL, Wazer DE, Watanabe K, Band V, 1996 Identification of a novel serine protease-like gene, the expression of which is down-regulated during breast cancer progression. Cancer Res 56: 3371–3379.PubMedGoogle Scholar
  14. 14.
    Kovacs K, Lloyd RV, Horvath E, et al, 1989 Silent somatotroph adenomas of the human pituitary: a morphologic study of three cases including immunocytochemistry, electron microscopy, in vitro examination and in situ hybridization. Am J Pathol 34: 345–353.Google Scholar
  15. 15.
    Kovacs K, Scheithauer BW, Horvath E, Lloyd RV, 1996 The World Health Organization classification of adenohypophysial neoplasms. A proposed five-tier scheme. Cancer 78: 502–510.CrossRefGoogle Scholar
  16. 16.
    Rotondo F, Scheithauer BW, Kovacs K, Bell DC, 2009 Rab 3B immunoexpression in human pituitary adenomas. Appl Immunohistochem Mol Morphol 17: 185–188.CrossRefGoogle Scholar
  17. 17.
    Nakagawa SA, Lopes A, Lopes de Carvalho A, et al, 2010 Nitric oxide synthases, cyclogenases-2, nitrotyrosine and angiogenesis in chondrosarcoma and their relation to prognosis. J Bone Joint Surg Am 92: 1738–1746.CrossRefGoogle Scholar
  18. 18.
    Bharaz BB, Luo LY, Jung K, Stephan C, Diamandis EP, 2002 identification of single nucleotide polymorphisms in human kallikrein 10 (KLK 10) gene and their association with prostate, breast, testicular, ovarian cancers. Prostate 51: 35–41.CrossRefGoogle Scholar
  19. 19.
    Feng B, Xu WB, Zheng MH, et al, 2006 Clinical significance of human kallikrein 10 gene expression in colorectal cancer and gastric cancer. J Gastroenterol Hepatol 21:1596–1603.CrossRefGoogle Scholar
  20. 20.
    Luo LY, Grass L, Howarth DJC, Thibault P, Ong H, Diamandis EP, 2001 Immunofluorometric assay of human kallikrein 10 and its identification in biological fluids and tissues. Clin Chem 47: 237–246.PubMedGoogle Scholar
  21. 21.
    Jones TH, Figueroa CD, Smith CM, Cullen DR, Bhoola KD, 1992 Tissue kallikrein is associated with prolactin-secreting cells within human growth hormone-secreting adenomas. J Endocrinol 134: 149–154.CrossRefGoogle Scholar
  22. 22.
    Kizuki K, Kitagawa A, Takahashi M, Moriya H, Kudo M, Noguchi T, 1990 Immunohistochemical localization of kallikrein within the prolactin-producing cells of the rat anterior pituitary gland. J Endocrinol 127: 317–323.CrossRefGoogle Scholar
  23. 23.
    Hatala MA, Powers CA, 1988 Glandular kallikrein in estrogen-induced pituitary tumors: time course of induction and correlation with prolactin. Cancer Res 48: 4158–4162.PubMedGoogle Scholar
  24. 24.
    Clements JA, Fuller FJ, McNally M, Nikolanidis I, Funder JW, 1986 Estrogen regulation of kallikrein gene expression in the rat anterior pituitary. Endocrinology 119: 268–273.CrossRefGoogle Scholar
  25. 25.
    Pritchett DB, Roberts JL, 1987 Dopamine regulates expression of the glandular-type kallikrein gene at the transcriptional level in the pituitary. Proc Natl Acad Sci USA 84: 5545–5549.CrossRefGoogle Scholar
  26. 26.
    Fuller PJ, Matheson BA, MacDonald RJ, Verity K, Clements JA, 1988 Kallikrein gene expression in estrogen-induced pituitary tumors. Moll Cell Endocrinol 60: 225–232.CrossRefGoogle Scholar
  27. 27.
    Powers CA, 1986 Anterior pituitary glandular kallikrein: trypsin activation and estrogen regulation. Mol Cell Endocrinol 46: 163–174.CrossRefGoogle Scholar
  28. 28.
    Xi Z, Klokk TI, Korkmaz K, et al, 2004 Kallikrein 4 is a predominantly nuclear protein and is overexpressed in prostate cancer. Cancer Res 64: 2365–2370.CrossRefGoogle Scholar
  29. 29.
    Zhang SQ, Cai B, Liu L, He YY, Yang YX, Wan XP, 2009 Kallikrein 4 overexpression in endometrial carcinoma and upregulation by estrogen via mitogen-activated protein kinase signal pathway. Int J Gynecol Cancer 19: 1377–1383.CrossRefGoogle Scholar
  30. 30.
    Casanueva FF, Molitch ME, Schlechte JA, et al, 2006 Guidelines of the pituitary society for the diagnosis and management of prolactinomas. Clin Endocrinol 65: 265–273.CrossRefGoogle Scholar
  31. 31.
    Beck-Peccoz P, Brucker-Davis F, Persani L, Smallridge RC, Weintraub BD, 1996 Thyrotropin-secreting pituitary tumors. Endocr Rev 17: 610–638.PubMedPubMedCentralGoogle Scholar
  32. 32.
    Sanno N, Teramoto A, Matsuno A, Inada K, Itoh J, Osamura RY, 1994 Clinical and immunohisto chemical studies on TSH-secreting pituitary adenoma: its multihormonality and expression of Pit-1. Mod Pathol 7: 893–899.PubMedGoogle Scholar
  33. 33.
    Adriannse R, Brabant G, Endert E, Bemelman FJ, Wiersinga WM, 1994 Pulsatile thyrotropin and prolactin secretion in a patient with a mixed thyrotropin-and prolactin-secreting pituitary adenoma. Eur J Endocrinol 130: 113–120.CrossRefGoogle Scholar
  34. 34.
    Powers CA, Hatala MA, 1986 Dopainergic regulation of the estrogen-induced glandular kallikrein in the rat anterior pituitary. Neuroendocrinology 44: 462–469.CrossRefGoogle Scholar
  35. 35.
    Abech DD, Moratelli HB, Leite SC, Oliveira MC, 2005 Effects of estrogen replacement therapy on pituitary size, prolactin and thyroid-stimulating hormone concentrations in menopausal women. Gynecol Endocrinol 21: 223–226.CrossRefGoogle Scholar
  36. 36.
    Paliouras M, Diamandis EP, 2006 The kallikrein world: an update on the human tissue kallikreins. Biol Chem 387: 643–652.CrossRefGoogle Scholar
  37. 37.
    Luo LY, Katsaros D, Scorilas A, et al, 2001 Prognostic value of human kallikrein 10 expression epithelial ovarian carcinoma. Clin Cancer Res 7: 2372–2379.PubMedGoogle Scholar
  38. 38.
    Roman-Gomez J, Jimenez-Velasco A, Agirre X, et al, 2004 The normal epithelial cell-specific 1 (NES1) gene, a candidate tumor suppressor gene on chromosome 19q13.3-4, is downregulated by hypermethylation in acute lymphoblastic leukemia. Leukemia 18: 362–365.CrossRefGoogle Scholar
  39. 39.
    Yousef GM, Stephan C, Scorilas A, et al, 2003 Differential expression of the human kallikrein gene 14 (KLK 14) in normal and cancerous prostatic tissues. Prostate 56: 287–292.CrossRefGoogle Scholar
  40. 40.
    Yousef GM, Scorilas A, Nakamura T, et al, 2003 The prognostic value of the human kallikrein gene 9 (KLK9) in breast cancer. Breast Cancer Res Treat 78: 149–158.CrossRefGoogle Scholar
  41. 41.
    Yu H, Levesque MA, Clark GM, Diamandis EP, 1998 Prognostic value of prostate0specific antigen for women with breast cancer: a large United States cohort study. Clin Cancer Res 4: 1489–1497.PubMedGoogle Scholar
  42. 42.
    Yu H, Giai M, Diamandis EP, et al, 1995 Prostate-specific antigen is a new favorable prognostic indicator for women with breast cancer. Cancer Res 55: 2104–2110.PubMedGoogle Scholar

Copyright information

© Hellenic Endocrine Society 2015

Authors and Affiliations

  • Fabio Rotondo
    • 1
    • 2
  • Antonio Di Ieva
    • 3
  • Kaiman Kovacs
    • 1
    • 2
  • Michael D. Cusimano
    • 3
  • Luis V. Syro
    • 4
  • Eleftherios P. Diamandis
    • 5
  • George M. Yousef
    • 1
    • 2
  1. 1.Department of Laboratory Medicine, and the Keenan Research Centre for Biomedical Science at the Li Ka Shing Knowledge InstituteSt. Michael’s HospitalTorontoCanada
  2. 2.Department of Laboratory Medicine and Pathobiology, St. Michael’s HospitalUniversity of TorontoTorontoCanada
  3. 3.Department of Neurosurgery, St. Michael’s HospitalUniversity of TorontoTorontoCanada
  4. 4.Department of NeurosurgeryHospital Pablo Tobon Uribe and Clinica MedellinMedellinColombia
  5. 5.Departments of Pathology and Laboratory Medicine, Division of Clinical Biochemistry, Mount Sinai Hospital and Clinical BiochemistryUniversity Health NetworkTorontoCanada

Personalised recommendations